Market's view on Rua Life Sci.
Published on April 2024
- There is potential concern within the medical industry about the reliance on animal parts due to the risk of contamination, exemplified by bird flu discovered in US milk. This could be disastrous if similar contamination is found in Australian and New Zealand milk, the main BSE-free sources for medical-grade cattle products.
- A significant discussion surrounds RUA’s shift from financing the development of heart valves to selling the textile material used in making these valves to larger companies.
- Enthusiasm is expressed regarding a patented heart valve and the start of commercial talks, with expectations of a near-term commercial deal, aiming for a target price of 50p per share.
- An ongoing testing agreement with a major company is mentioned, examining new composite materials that could potentially revolutionize the TAVR segment of heart valve production.
- Some watchers express skepticism and caution, labelling the stock a risky buy, while others are optimistic, urging immediate buying to avoid missing out on expected substantial price movements.
- A warning is highlighted about the dangers of relying on a supply chain dependent on animal tissue from regions free of BSE, underscoring the importance of developing alternative materials in the event of a supply chain disruption.